Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full-body symptoms.
Copyright © 2024 | WordPress Theme by MH Themes